Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Terguride

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Terguride
Clinical data
Trade namesTeluron
Other namesDironyl; Mysalfon;trans-Dihydrolisuride; Transdihydrolisuride; TDHL; SH-406; VUFB-6638; ZK-31224;N,N-Diethyl-N'-[(8α)-6-methylergolin-8-yl]urea
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 3-[(6aR,9S,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard(EPA)
ECHA InfoCard100.048.732Edit this at Wikidata
Chemical and physical data
FormulaC20H28N4O
Molar mass340.471 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
  • InChI=1S/C20H28N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,11,14,16,18,21H,4-5,9-10,12H2,1-3H3,(H,22,25)/t14-,16+,18+/m0/s1
  • Key:JOAHPSVPXZTVEP-YXJHDRRASA-N
  (verify)

Terguride (INNTooltip International Nonproprietary Name,JANTooltip Japanese Accepted Name), sold under the brand nameTeluron, is aserotonin receptorantagonist anddopamine receptoragonist of theergoline family. It is approved for and used as aprolactin inhibitor in the treatment ofhyperprolactinemia (high prolactin levels) inJapan.[1][2] Terguride is takenby mouth.[citation needed]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Terguride acts as anagonist of thedopamineD2 receptor and as anantagonist of theserotonin5-HT2A and5-HT2B receptors, among other actions.[citation needed]

As an antagonist of the 5-HT2B receptor, terguride is not associated withcardiac valvulopathy.[3]

Activities of terguride at various sites[4][5][6][7]
SiteAffinity (Ki [nM])Efficacy (Emax [%])Action
D128??
D2S0.8139Partial agonist
D2L1.10Silent antagonist
D31.036Partial agonist
D48.10Silent antagonist
D523??
5-HT1A3.571Partial agonist
5-HT1B25737Partial agonist
5-HT1D1662Partial agonist
5-HT2A4.849Partial agonist
5-HT2B7.10Silent antagonist
5-HT2C480Silent antagonist
5-HT78–42??
α1A3.50Silent antagonist
α1B35??
α1D3.9??
α2A0.300Silent antagonist
α2B0.450Silent antagonist
α2C0.760Silent antagonist
α2D1.5??
β1661??
β220??
H1339??
M1>10,000??
Notes: All receptors are human except α2D-adrenergic, which is rat (no human counterpart), and 5-HT7, which wasguinea pig.[4][7]

Research

[edit]

Serotonin stimulates the proliferation of pulmonary artery smooth muscle cells, and induces fibrosis in the wall of pulmonary arteries. Together, this causes vascular remodeling and narrowing of the pulmonary arteries. These changes result in increased vascular resistance and PAH. Due to the potential anti-proliferative and anti-fibrotic activity of terguride, this potential medicine could offer the hope of achieving reversal of pulmonary artery vascular remodeling and attenuation of disease progression.[8] In May 2008, terguride was grantedorphan drug status for the treatment ofpulmonary arterial hypertension.[9]In May 2010Pfizer purchased worldwide rights for the drug.[10] However, development was discontinued in 2011.

See also

[edit]

References

[edit]
  1. ^"List of 5HT3 receptor antagonists (5hydroxytryptamine receptor antagonists)". Archived fromthe original on 2016-03-03.
  2. ^"Terguride - AdisInsight".
  3. ^Zajdel P, Bednarski M, Sapa J, Nowak G (April 2015). "Ergotamine and nicergoline - facts and myths".Pharmacol Rep.67 (2):360–3.doi:10.1016/j.pharep.2014.10.010.PMID 25712664.S2CID 22768662.
  4. ^abMillan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes".J Pharmacol Exp Ther.303 (2):791–804.doi:10.1124/jpet.102.039867.PMID 12388666.S2CID 6200455.
  5. ^Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor".J Pharmacol Exp Ther.303 (2):805–14.doi:10.1124/jpet.102.039875.PMID 12388667.S2CID 35238120.
  6. ^Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes".J Pharmacol Exp Ther.303 (2):815–22.doi:10.1124/jpet.102.039883.PMID 12388668.S2CID 19260572.
  7. ^ab"PDSP Database - UNC".pdsp.unc.edu. Archived fromthe original on 13 April 2021. Retrieved15 January 2022.
  8. ^Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, et al. (2015)."5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure".BioMed Research International.2015 438403.doi:10.1155/2015/438403.PMC 4312574.PMID 25667920.
  9. ^Presseportal (Swiss press portal, in German)
  10. ^"TheDay.com 5/10/2010". Archived fromthe original on 2016-03-05. Retrieved2010-05-21.
Prolactin inhibitors
Anti-inflammatory products
forvaginal administration
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Ergolines
(incl.lysergines)
Clavines
(6,8-dimethylergolines)
Lysergamides
(lysergic acid amides)
Ergopeptines
(peptide ergolines)
Partial ergolines
Related compounds
Natural sources
Retrieved from "https://en.wikipedia.org/w/index.php?title=Terguride&oldid=1322837139"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp